PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 142 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2018. The put-call ratio across all filers is 1.87 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,000 | -87.5% | 120 | -70.0% | 0.00% | -100.0% |
| Q1 2019 | $16,000 | +100.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $8,000 | -98.7% | 400 | -95.4% | 0.00% | -97.7% |
| Q1 2018 | $594,000 | -51.4% | 8,723 | -29.4% | 0.04% | -56.1% |
| Q4 2017 | $1,222,000 | +61.6% | 12,359 | -39.2% | 0.10% | +36.1% |
| Q1 2017 | $756,000 | +283.8% | 20,335 | +1104.0% | 0.07% | +157.1% |
| Q2 2015 | $197,000 | -50.6% | 1,689 | 0.0% | 0.03% | -49.1% |
| Q1 2015 | $399,000 | +454.2% | 1,689 | +463.0% | 0.06% | +450.0% |
| Q3 2014 | $72,000 | -32.1% | 300 | -81.2% | 0.01% | -28.6% |
| Q2 2014 | $106,000 | – | 1,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |